Innovent's 9 mg mazdutide Phase 3 record flips to unknown status
A Phase 3 trial listing for Innovent's mazdutide 9 mg obesity drug in China flipped to "unknown" status in the federal trial registry, a paperwork signal that has no bearing on the drug's strong weight-loss results but shows how such changes can disappear from public view.
On Aug. 31, 2026, the registry entry for Innovent Biologics' Phase 3 study of mazdutide (IBI362) 9 mg in Chinese adults with obesity changed from "active, not recruiting" to "unknown," according to GLP-1 Briefing, a service that tracks changes to trial registries that are otherwise overwritten without leaving a public trace [1]. An "unknown" status typically means the sponsor has not verified the record within the registry's expected reporting window, not that the trial has stopped or failed [1].
The trial in question is part of the GLORY-2 program, which tested mazdutide 9 mg plus lifestyle changes against placebo in 462 Chinese adults with obesity, including 16% with type 2 diabetes [2]. At week 60, the 9 mg group lost an average of 18.55% of body weight, compared with 3.02% for placebo [2]. Among participants without type 2 diabetes, average weight loss reached 20.08%, versus 2.81% on placebo, and nearly half of that group, 48.7%, lost 20% or more of their body weight [2]. Innovent has said it plans to submit a new drug application for mazdutide 9 mg to China's National Medical Products Administration "in the near term" [2].
Safety data from GLORY-2 showed no new signals. Most gastrointestinal side effects were mild to moderate and temporary, and 2.9% of the mazdutide group stopped treatment early because of side effects, compared with none in the placebo group [2]. Mazdutide is a dual glucagon/GLP-1 receptor agonist that Innovent develops and markets in China under a license from Eli Lilly, and it is already approved by China's regulator for weight management and type 2 diabetes at other doses, though not yet at the 9 mg dose used in GLORY-2 [2].
The registry status change itself is separate from these clinical results. GLP-1 Briefing notes that ClinicalTrials.gov overwrites a record each time it changes and keeps no public history of the prior entry, so a status flip like this one is only visible because the service snapshots the registry multiple times a day and compares versions [1]. The change is described as an administrative lapse rather than a clinical event, meaning it does not by itself indicate a problem with the trial's data or Innovent's regulatory plans [1].
Why it matters for patients
Mazdutide is not approved or sold in the United States, so this development does not affect anyone currently taking a GLP-1 medicine here. But it illustrates a broader transparency issue in how drug trials are tracked. When a sponsor's registry entry lapses into "unknown" status, the public record can lose visibility into a late-stage obesity trial's progress, even though the underlying study may be proceeding normally [1]. For US patients weighing future GLP-1 options, the GLORY-2 results themselves remain notable: a 20% average weight loss over 60 weeks in participants without diabetes is among the higher figures reported for a GLP-1-class drug in a Phase 3 obesity trial [2]. Whether mazdutide will ever be reviewed or sold in the US is not addressed in these sources and is not yet known.
What happens next
Innovent has said it intends to file for approval of mazdutide 9 mg with China's NMPA "in the near term," though no specific submission date has been given [2]. It is not yet known when or whether the trial's registry status will be corrected back from "unknown," or whether the lapse reflects a routine administrative delay or something else, since GLP-1 Briefing categorizes this type of change as an administrative signal rather than a clinical one [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.